Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Integrating Next-Generation SERDs in Advanced Breast Cancer 

Clinical Thought

Experts answer your questions related to the program, “Beyond Resistance: Integrating Next-Generation SERDs into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: May 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This educational activity is intended for medical oncologists, pathologists, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients and colleagues on the mechanisms of action and biologic rationales for using next-generation SERDs in endocrine-resistant ER-positive/HER2-negative ABC

  • Design individualized treatment plans incorporating next-generation SERDs for appropriate patients with ER-positive/HER2-negative ABC based on biomarker testing results, patient factors, clinical data, and expert recommendations

  • Appraise the potential clinical implications of emerging data and ongoing trials evaluating next-generation SERDs on management of patients with ER-positive/HER2-negative ABC

  • Implement interprofessional team processes and workflows to identify actionable ESR1 mutations and support timely intervention in patients with ER-positive/HER2-negative ABC

  • Collaborate with interdisciplinary colleagues to effectively manage treatment-related toxicities and support treatment adherence/persistence to next-generation SERD therapy

Disclosure

Primary Author

Mabel Mardones, MD: consultant/advisor/speaker: Agendia, AstraZeneca, Epic Sciences, Genentech, Lilly, Puma, Sanofi, Seattle Genetics, Stemline.

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AADI Bioscience, Agendia, Amgen, Aptitude, AstraZeneca, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Duality, Eisai, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead, Guardant Health, HiberCell, Jazz, Johnson & Johnson, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre, Puma, RayzeBio, Roche, Sanofi, Seagen, Stemline, Summit, Tempus, TerSera.

Michelle Shiller, DO: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Lilly, Merck, Pfizer, RevMed, Roche.